Larinate 200 Kit Tablet is a fixed-dose combination medication containing Artesunate 200 mg, Sulphadoxine 500 mg, and Pyrimethamine 25 mg, primarily indicated for the treatment of uncomplicated Plasmodium falciparum malaria. Artesunate, a potent artemisinin derivative, acts rapidly against the erythrocytic stages of the parasite, leading to a swift reduction in parasitemia. Sulphadoxine and Pyrimethamine, antifolate agents, inhibit folic acid synthesis in the parasite, providing a synergistic effect that enhances therapeutic efficacy and helps prevent resistance development. This combination is especially valuable in regions with documented resistance to monotherapy. Larinate 200 Kit Tablet should be administered as per recommended dosing guidelines, typically as a single-dose regimen or over a short course, depending on clinical judgment and local protocols. The medication is contraindicated in patients with known hypersensitivity to any component, severe hepatic or renal impairment, and in pregnant women during the first trimester unless the benefits outweigh risks. Common adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and hematologic abnormalities. Close monitoring is advised during therapy. Larinate 200 Kit Tablet offers an effective, convenient treatment option for malaria, contributing to improved patient compliance and outcomes in endemic areas.